Barbara A Fries Hastings

Title: Barbara A Fries Hastings - Innovator in Treating Macular Degeneration

Introduction:

Barbara A Fries Hastings, an esteemed inventor and scientist, has dedicated her career to finding innovative solutions for the treatment of macular degeneration. With her groundbreaking patent and notable contributions to the field, she has made a significant impact in improving the lives of patients suffering from this debilitating disease. Working at Somerset Pharmaceuticals, Inc., Barbara's expertise and dedication have propelled her to the forefront of medical research.

Latest Patents:

Barbara A Fries Hastings holds one remarkable patent in the field of ophthalmology. Her patented invention revolves around a method of treating macular degeneration. The patented method involves administering a therapeutically effective amount of L-deprenyl or a pharmaceutically acceptable acid addition salt thereof to patients with macular degeneration. This treatment approach has demonstrated positive outcomes in ameliorating the disease, offering hope to countless individuals battling vision problems associated with macular degeneration.

Career Highlights:

Barbara's career has been marked by her commitment to advancing the field of ophthalmology. Her work at Somerset Pharmaceuticals, Inc., has been instrumental in the development of groundbreaking treatments for various eye disorders, with a particular focus on macular degeneration. Her expertise and dedication have not only earned her recognition within the company but also among her peers in the scientific community.

Collaborations:

Throughout her career, Barbara has actively collaborated with fellow researchers, medical professionals, and scientists in the pursuit of innovative approaches to treating macular degeneration. By fostering partnerships and working in multidisciplinary teams, she has been able to pool knowledge and expertise to further advance the field. Collaborations have played a crucial role in bringing diverse perspectives and expertise together, ultimately contributing to the success of her research endeavors.

Conclusion:

Barbara A Fries Hastings is a leading innovator in the treatment of macular degeneration, renowned for her groundbreaking contributions in the field. Her patented method of administering L-deprenyl or its pharmaceutically acceptable acid addition salts for the treatment of macular degeneration offers hope to patients worldwide. With her ongoing dedication and collaborative approach, Barbara continues to pave the way for transformative advancements in ophthalmology. Her work demonstrates the power of innovation and the profound impact it can have on improving quality of life for individuals living with macular degeneration.